Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 3/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 12/20 | 0.44 |
| ▸ | CCND1 | P24385 | 11/20 | 0.44 |
| ▸ | CDK4 | P11802 | 7/20 | 0.44 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.44 |
| ▸ | TNK2 | Q07912 | 3/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.44 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.44 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.44 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 8/20 | 0.44 |
| ▸ | CDK6 | Q00534 | 5/20 | 0.44 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.44 |
| ▸ | CDK9 | P50750 | 1/20 | 0.44 |
| ▸ | CCND2 | P30279 | 3/20 | 0.42 |
| ▸ | CCND3 | P30281 | 3/20 | 0.42 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.41 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL916708 | 0.92 | TNK2 (0.49) | MAPK14LCKCDK2CCND1CDK4 | |
| SCHEMBL3576421 | 0.89 | MAPK14 (0.46) | MAPK14LCKCDK2CCND1CDK4 | |
| SCHEMBL3577496 | 0.88 | MAPK14 (0.46) | MAPK14LCKCDK2CCND1CDK4 | |
| SCHEMBL916495 | 0.87 | CDK2 (0.46) | MAPK14LCKCDK2CCND1CDK4 | |
| SCHEMBL916496 | 0.85 | CCNE1 (0.42) | MAPK14LCKCDK2CCND1CDK4 | |
| SCHEMBL917268 | 0.85 | MAPK14 (0.59) | MAPK14LCKCDK2CCND1CDK4 | |
| SCHEMBL916838 | 0.85 | MAPK14 (0.43) | MAPK14LCKCDK2CCND1CDK4 | |
| SCHEMBL3677049 | 0.85 | MAPK14 (0.64) | MAPK14LCKCDK2CCND1CDK4 | |
| SCHEMBL915589 | 0.84 | MAPK14 (0.43) | MAPK14LCKCDK2CCND1CDK4 | |
| SCHEMBL916228 | 0.83 | MAPK14 (0.59) | MAPK14LCKCDK2CCND1CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221600-A1 | PYRIDO-PYRIDIMIDINE DERIVATIVES USEFUL AS ANTIINFLAMMATORY AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-09-03 | — | — | US | claimed |
| US-20110021473-A1 | INHIBITORS OF PHOSPHODIESTERASE TYPE-IV | RANBAXY LABORATORIES LIMITED | 2011-01-27 | — | — | US | disclosed |
| US-20100029728-A1 | PHOSPHODIESTERASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2010-02-04 | — | — | US | disclosed |
| US-20100004215-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2010-01-07 | — | — | US | disclosed |
| EP-2111861-A1 | Compositions of phosphodiesterase type IV inhibitors | Ranbaxy Laboratories Limited (IN) | 2009-10-28 | — | — | EP | disclosed |
| US-20090221600-A1 | PYRIDO-PYRIDIMIDINE DERIVATIVES USEFUL AS ANTIINFLAMMATORY AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-09-03 | — | — | US | disclosed |
| US-20090221664-A1 | PHARMACEUTICAL COMPOSITIONS OF MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-09-03 | — | — | US | disclosed |
| EP-2066661-A2 | PHOSPHODIESTERASE INHIBITORS | Ranbaxy Laboratories Limited (IN) | 2009-06-10 | — | — | EP | disclosed |
| US-20090054382-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2009-02-26 | — | — | US | disclosed |
| US-20080207659-A1 | INHIBITORS OF PHOSPHODIESTERASE TYPE 4 | RANBAXY LABORATORIES LIMITED (IN) | 2008-08-28 | — | — | US | disclosed |
| EP-1958947-A1 | Inhibitors of phosphodiesterase type 4 | Ranbaxy Laboratories Limited (IN) | 2008-08-20 | — | — | EP | disclosed |
| EP-1948164-A1 | PHARMACEUTICAL COMPOSITIONS OF MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES, LTD. (IN) | 2008-07-30 | — | — | EP | disclosed |
| WO-2008035316-A2 | PHOSPHODIESTERASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2008-03-27 | — | — | WO | disclosed |
| WO-2007045979-A1 | PHARMACEUTICAL COMPOSITIONS OF MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207659-A1 | INHIBITORS OF PHOSPHODIESTERASE TYPE 4 | PDE4A, PDE4B, PDE4C | MAPK14 1599/4885LCK 847/4885CDK2 827/4885 |
| US-20090221600-A1 | PYRIDO-PYRIDIMIDINE DERIVATIVES USEFUL AS ANTIINFLAMMATORY AGENTS | PNPO, TPMT, NOD1 | MAPK14 1920/4885LCK 469/4885CDK2 393/4885 |
| US-20090221664-A1 | PHARMACEUTICAL COMPOSITIONS OF MUSCARINIC RECEPTOR ANTAGONISTS | ADRB2, ADRB1, ADRA2C | MAPK14 238/4885LCK 348/4885CDK2 1168/4885 |
| US-20100029728-A1 | PHOSPHODIESTERASE INHIBITORS | PDE4A, PDE4B, PDE4C | MAPK14 1715/4885LCK 910/4885CDK2 967/4885 |
| US-20100004215-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | PDE4B, PDE4A, PDE3B | MAPK14 136/4885LCK 551/4885CDK2 944/4885 |
| US-20110021473-A1 | INHIBITORS OF PHOSPHODIESTERASE TYPE-IV | PDE4A, PDE4B, PDE4C | MAPK14 1108/4885LCK 1680/4885CDK2 912/4885 |
| US-20090054382-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | PDE4B, PDE4A, PDE3B | MAPK14 136/4885LCK 590/4885CDK2 936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.